SCHEMBL31067148

SCHEMBL31067148

Fc1cccc(N2CCC3(CC2)OCCO3)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 5/20 0.50
SLC6A4 P31645 5/20 0.50
SLC6A3 Q01959 5/20 0.50
ALDH1A1 P00352 5/20 0.49
HPGD P15428 3/20 0.49
MAPT P10636 3/20 0.49
KDM4E B2RXH2 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
LMNA P02545 1/20 0.49
GAA P10253 1/20 0.49
MAPK1 P28482 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
RCE1 Q9Y256 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
LGMN Q99538 1/20 0.49
TSHR P16473 2/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14337144 0.83 LGMN (0.47) SLC6A2SLC6A4SLC6A3ALDH1A1HPGD
SCHEMBL14117684 0.81 RAB9A (0.57) ALDH1A1HPGDMAPTKDM4ELMNA
SCHEMBL12160679 0.81 LGMN (0.49) SLC6A2SLC6A4SLC6A3ALDH1A1MAPK1
SCHEMBL20723355 0.81 LGMN (0.49) SLC6A2SLC6A4SLC6A3ALDH1A1HPGD
SCHEMBL3795448 0.80 LGMN (0.54) ALDH1A1HPGDMAPTKDM4ENPSR1
SCHEMBL612022 0.79 LMNA (0.55) ALDH1A1HPGDMAPTKDM4ELMNA
SCHEMBL17893812 0.79 LGMN (0.54) SLC6A2SLC6A4SLC6A3ALDH1A1HPGD
SCHEMBL20699709 0.78 BPTF (0.54) ALDH1A1MAPTGAAKMT2AMEN1
SCHEMBL10373948 0.78 BPTF (0.54) ALDH1A1MAPTGAAKMT2AMEN1
SCHEMBL14117690 0.78 ADRB1 (0.56) ALDH1A1HPGDMAPTKDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4673431-A1 HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER Novartis AG (CH) 2026-01-07 EP disclosed
US-12129246-B1 Hydroquinazoline derivatives for the treatment of a disease or disorder NOVARTIS AG (CH) 2024-10-29 US disclosed
US-20240336598-A1 HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2024-10-10 US disclosed
WO-2024180499-A1 HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER NOVARTIS AG (CH) 2024-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12129246-B1 Hydroquinazoline derivatives for the treatment of a disease or disorder RECQL, NRAS, RAB1A SLC6A2 201/4885SLC6A4 617/4885SLC6A3 162/4885
US-20240336598-A1 HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER RECQL, NRAS, RAB1A SLC6A2 201/4885SLC6A4 617/4885SLC6A3 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.